IP Library › Granted Patent US 12,428,654
Granted Patent B1
US 12,428,654 · App. 18/929,934 · Granted Sep 30, 2025

Composition for regulating production of proteins

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C12N15/86C07K14/4702C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,654
App. No.
18/929,934
Granted
Sep 30, 2025
Kind
B1
Abstract

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a protein such as SUMO.

Claims (8)

1. A composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides that encodes a sequence of messenger ribonucleic acid (mRNA) that encodes for a protein, wherein the sequence of nucleotides is 95% to 100% identical to SEQ ID NO. 2.

2. The composition of claim 1 , wherein the RP is configured to be delivered to a target cell.

3. The composition of claim 1 , wherein the RP is encased in a protein coat, a lipid vesicle, or any combination thereof.

4. The composition of claim 1 , wherein the RP is encased in a viral vector.

5. The compositions of claim 4 , wherein the viral vector is one of a double-stranded DNA virus, a single-stranded DNA virus, a single-stranded RNA virus, or a double-stranded RNA virus.

6. The compositions of claim 4 , wherein the viral vector is an adeno-associated virus.

7. The composition of claim 1 , wherein the protein is small ubiquitin-like modifier (SUMO).

8. A composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides for encoding a sequence of messenger ribonucleic acid (mRNA) that encodes for a protein, wherein the sequence of nucleotides is 95-100% identical to SEQ ID NO. 3, and wherein the protein is small ubiquitin-like modifier (SUMO).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072061/0023 →
References Cited (29)
US 11085055B2 · Mallol et al. · 2021 [cited by applicant]
US 11162102B2 · Minshull et al. · 2021 [cited by applicant]
US 11530423B1 · Thompson · 2022 [cited by applicant]
US 11873505B2 · Thompson · 2024 [cited by applicant]
US 12018274B2 · Thompson · 2024 [cited by applicant]
US 12134770B1 · Thompson · 2024 [cited by applicant]
US 20240026377A1 · Thompson · 2024 [cited by applicant]
CA 2721333A1 · 2009 [cited by applicant]
O'Brien et al. “Overview of microRNA biogenesis, mechanisms of actions, and circulation.” Frontiers in endocrinology 9 (2018): 402. [cited by applicant]
Gorski et al. “RNA-based recognition and targeting: sowing the seeds of specificity.” Nature Reviews Molecular Cell Biology 18.4 (2017): 215-228. [cited by applicant]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112. [cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848. [cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166. [cited by applicant]
Denzler et al. “Impact of microRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression.” Molecular cell 64.3 (2016): 565-579. [cited by applicant]
Van Den Berg et al. “Design of effective primary microRNA mimics with different basal stem conformations.” Molecular Therapy Nucleic Acids 5 (2016). [cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506. [cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253. [cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494. [cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016. [cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675. [cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010). [cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023). [cited by applicant]
GenBank EGFR Sequence (2023). [cited by applicant]
GenBank EGF Sequence (2023). [cited by applicant]
NCBI search results for Seq ID No. 5 (2024). [cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024). [cited by applicant]
GenBank FLT3 Sequence (2024). [cited by applicant]